相似文献
1
Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference.
Oncoimmunology. 2014 Jun 25;3:e29380. doi: 10.4161/onci.29380. eCollection 2014.
2
-Glycosylation regulates ligand-dependent activation and signaling of vascular endothelial growth factor receptor 2 (VEGFR2).
J Biol Chem. 2019 Aug 30;294(35):13117-13130. doi: 10.1074/jbc.RA119.008643. Epub 2019 Jul 15.
3
Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.
Cell. 2014 Feb 13;156(4):744-58. doi: 10.1016/j.cell.2014.01.043.
4
Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
Pharmacol Ther. 2018 Nov;191:92-122. doi: 10.1016/j.pharmthera.2018.06.003. Epub 2018 Jun 29.
5
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.
BMC Cancer. 2010 Dec 15;10:683. doi: 10.1186/1471-2407-10-683.
6
The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells.
J Biol Chem. 2011 Dec 23;286(51):44045-44056. doi: 10.1074/jbc.M111.278754. Epub 2011 Oct 24.
7
Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy.
Sci Rep. 2015 Dec 9;5:17946. doi: 10.1038/srep17946.
8
Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Cancer Lett. 2016 Nov 1;382(1):44-52. doi: 10.1016/j.canlet.2016.08.020. Epub 2016 Aug 26.
9
Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment.
Glycobiology. 2014 Dec;24(12):1283-90. doi: 10.1093/glycob/cwu083. Epub 2014 Aug 12.
10
Sulfated polysaccharide JCS1S2 inhibits angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Carbohydr Polym. 2019 Mar 1;207:502-509. doi: 10.1016/j.carbpol.2018.11.091. Epub 2018 Dec 6.
引用本文的文献
1
Galectin functions in cancer-associated inflammation and thrombosis.
Front Cardiovasc Med. 2023 Feb 17;10:1052959. doi: 10.3389/fcvm.2023.1052959. eCollection 2023.
2
Targeting galectin-driven regulatory circuits in cancer and fibrosis.
Nat Rev Drug Discov. 2023 Apr;22(4):295-316. doi: 10.1038/s41573-023-00636-2. Epub 2023 Feb 9.
3
ST6Gal1: Oncogenic signaling pathways and targets.
Front Mol Biosci. 2022 Aug 29;9:962908. doi: 10.3389/fmolb.2022.962908. eCollection 2022.
4
Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways.
Nat Commun. 2020 Dec 10;11(1):6330. doi: 10.1038/s41467-020-20108-0.
5
Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Cells. 2019 Sep 18;8(9):1102. doi: 10.3390/cells8091102.
6
ST6GAL1: A key player in cancer.
Oncol Lett. 2019 Aug;18(2):983-989. doi: 10.3892/ol.2019.10458. Epub 2019 Jun 7.
7
Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins.
Cell Commun Signal. 2019 Jun 17;17(1):65. doi: 10.1186/s12964-019-0371-1.
8
Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.
Int J Mol Sci. 2018 Jan 10;19(1):210. doi: 10.3390/ijms19010210.
9
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
Sci Rep. 2017 Apr 27;7(1):1217. doi: 10.1038/s41598-017-01279-1.
10
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.
Leukemia. 2016 Dec;30(12):2351-2363. doi: 10.1038/leu.2016.137. Epub 2016 May 20.
本文引用的文献
1
Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.
Cell. 2014 Feb 13;156(4):744-58. doi: 10.1016/j.cell.2014.01.043.
2
Vascular galectins: regulators of tumor progression and targets for cancer therapy.
Cytokine Growth Factor Rev. 2013 Dec;24(6):547-58. doi: 10.1016/j.cytogfr.2013.07.003. Epub 2013 Aug 12.
3
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.
Nat Med. 2013 Sep;19(9):1114-23. doi: 10.1038/nm.3291. Epub 2013 Aug 4.
4
Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.
J Exp Med. 2012 Oct 22;209(11):1985-2000. doi: 10.1084/jem.20111665. Epub 2012 Oct 1.
5
Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer.
Immunity. 2012 Mar 23;36(3):322-35. doi: 10.1016/j.immuni.2012.03.004.
6
Molecular mechanisms and clinical applications of angiogenesis.
Nature. 2011 May 19;473(7347):298-307. doi: 10.1038/nature10144.
7
Metabolism, cell surface organization, and disease.
Cell. 2009 Dec 24;139(7):1229-41. doi: 10.1016/j.cell.2009.12.008.
8
Modes of resistance to anti-angiogenic therapy.
Nat Rev Cancer. 2008 Aug;8(8):592-603. doi: 10.1038/nrc2442.
9
Vascular endothelial growth factor signaling pathways: therapeutic perspective.
Clin Cancer Res. 2006 Sep 1;12(17):5018-22. doi: 10.1158/1078-0432.CCR-06-1520.
10
Tumor angiogenesis: therapeutic implications.
N Engl J Med. 1971 Nov 18;285(21):1182-6. doi: 10.1056/NEJM197111182852108.
Zotero 插件